Related Experiment Video
Updated: Jan 13, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Respiratory syncytial virus (RSV) vaccine choices during pregnancy
Bing Wang1, Prabha Andraweera1, Gang Chen2
1Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia; Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
Insights
Australian pregnant women prefer free maternal Respiratory Syncytial Virus (RSV) vaccines, prioritizing safety and effectiveness. Preferences for promotion strategies varied among vaccine accepters and rejecters.
Area of Science:
- Public Health
- Vaccinology
- Maternal and Child Health
Background:
- Respiratory Syncytial Virus (RSV) is a major cause of infant respiratory illness.
- New maternal RSV vaccines and infant monoclonal antibodies offer protection.
- Understanding vaccine attitudes in pregnant populations is crucial for public health strategies.
Purpose of the Study:
- To assess Australian pregnant women's attitudes towards maternal RSV vaccination.
- To identify factors influencing decisions regarding RSV vaccination in pregnancy.
- To compare preferences between maternal vaccination and infant monoclonal antibody administration.
Main Methods:
- A cross-sectional online survey with a discrete choice experiment (DCE) design was used.
- Focus group discussions informed the DCE survey development.
- Mixed logit and latent class models analyzed survey data from 440 participants.
Main Results:
- Pregnant women strongly preferred a free maternal RSV vaccine with high effectiveness and low side effect risk.
- Two preference groups emerged: 'accepters/deliberators' (68.3%) and 'rejecters' (31.7%).
- Maternal RSV vaccination was significantly preferred over infant monoclonal antibodies (54.8% vs. 16.8%).
Conclusions:
- Maternal RSV vaccination is generally well-received by pregnant women when offered at no cost.
- Preference for promotional strategies differed between vaccine accepters and rejecters.
- Targeted communication strategies may be necessary to address varied attitudes towards RSV vaccination.
Objectives:
Respiratory Syncytial Virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants and can lead to fatal respiratory distress, especially in very young infants. New maternal RSV vaccines and infant monoclonal antibodies are now available. This study aims to understand RSV vaccine attitudes in Australian pregnant women.
Study Design:
The cross-sectional online survey employed a discrete choice experiment (DCE) design to quantify trade-offs and investigate decision-making patterns among pregnant women regarding the maternal RSV vaccine. A mixed-methods approach was used, with results from focus group discussions informing the development of the DCE survey.
Methods:
Any pregnant women aged ≥18 years in Australia were eligible to participate in the survey. During the survey, respondents were asked to choose between hypothetical scenarios, or optout option. Survey data were analysed using mixed logit and latent class models.
Results:
In total, 440 pregnant women participated and demonstrated a strong preference for a free RSV maternal vaccine with a lower risk of serious side effects and higher vaccine effectiveness. Latent class analysis revealed two distinct preference groups: "accepters/deliberators" and "rejecters". Compared to rejecters (31.7 %), accepters/deliberators (68.3 %) were more likely to be older, haver high household income and had received a pertussis vaccine, and were less likely to receive an influenza vaccine. Incentives to encourage vaccination were not supported by either group. Among rejecters, cost did not influence their vaccine preference, but text message reminders were more preferred. In contrast to accepters/deliberators, rejecters expressed a strong dislike for video advertisements. Participants showed a significantly higher preference for RSV maternal vaccination (54.8 %) versus infant monoclonal antibody injection (16.8 %) in a general preference question (p < 0.001).
Conclusions:
Maternal RSV vaccination at no cost was generally well received and preferred by pregnant women in this study, though preferences for promotion strategies varied.
More Related Videos
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Vaccinations
Teratogenicity
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in...

